In vitro cytotoxicity and antileishmanial activity of free quaternary halomethylated ammonium iodide and incorporated in nanoparticles.

Table 3: In vitro cytotoxicity and antileishmanial activity of free quaternary halomethylated ammonium iodide and incorporated in nanoparticles.

LC₅₀						EC₅₀	IS
Samples	haMP	huMDM	Detroit 551	Caco-2	U-937	EC₅₀	IS
C₆I	9.5 ± 0.3	> 200	39.3	> 200	9.5 ± 0.2	17.6 ± 1.0	0.53
PC₆I	> 200	> 200	> 200	> 200	> 200	0.4 ± 0.2	500
NPs	> 200	> 200	> 200	> 200	> 200	70.5 ± 10.0	2.8
Doxorubicin	< 1.5	20.2 ± 2.5	14.0 ± 1.1	0.14 ± 0.0	0.4 ± 0.1	NA	NA
Amphotericin B	53.8 ± 7.0	10.0 ± 1.2	NA	NA	32.2 ± 8.8	0.4 ± 0.1	134.5

Data represent the mean value ± SD (N = 3) (in μg/mL) of the median lethal concentration (LC50) and the median effective conentration (EC₅₀). MDMhu: Human monocyte-derived macrophages; MPha: Hamster's peritoneal macrophages; Caco-2 human colon adenocarcinoma cell line; Detroit 551: Human skin fibroblast cell line; NA: No apply; IS: Index of Selectivity calculated in huMDM cells by LC₅₀/EC₅₀; C₆I: Quaternary halomethylated ammonium iodide; PC₆I: Quaternary halomethylated ammonium iodide incorporated in Precirol^® nanoparticles.